Cumberland Pharmaceuticals Inc. (CPIX) Shareholder Equity
- 2026-06-30: Retained Earnings (Accumulated Deficit)USD $-34.37M; Stockholders' Equity Attributable to ParentUSD $17.44M; Stockholders' Equity, Including Portion Attributable to Noncontrolling InterestUSD $17.11M; Common Stock, Value, OutstandingUSD $51.81M.
- 2026-03-31: Retained Earnings (Accumulated Deficit)USD $-30.09M; Stockholders' Equity Attributable to ParentUSD $21.64M; Stockholders' Equity, Including Portion Attributable to Noncontrolling InterestUSD $21.30M; Common Stock, Value, OutstandingUSD $51.73M.
- 2025-12-31: Retained Earnings (Accumulated Deficit)USD $-26.80M; Stockholders' Equity Attributable to ParentUSD $24.88M; Stockholders' Equity, Including Portion Attributable to Noncontrolling InterestUSD $24.54M; Common Stock, Value, OutstandingUSD $51.68M.
- 2025-09-30: Retained Earnings (Accumulated Deficit)USD $-25.39M; Stockholders' Equity Attributable to ParentUSD $26.12M; Stockholders' Equity, Including Portion Attributable to Noncontrolling InterestUSD $25.80M; Common Stock, Value, OutstandingUSD $51.51M.
Cumberland Pharmaceuticals Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Common Stock, Value, Outstanding USD | Common Stock, Value, Issued USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Noncontrolling Interest, Increase from Sale of Parent Equity Interest USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-34.37M | $17.44M | $17.11M | $51.81M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-30.09M | $21.64M | $21.30M | $51.73M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-26.80M | $24.88M | $24.54M | $51.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-25.39M | $26.12M | $25.80M | $51.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-23.45M | $27.99M | $27.68M | $51.44M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-22.71M | $28.66M | $28.34M | $51.37M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-23.97M | $22.85M | $22.55M | $46.82M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-22.06M | $24.78M | $24.47M | $46.84M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-20.52M | $26.35M | $26.03M | $46.87M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-19.43M | $27.49M | $27.19M | $46.92M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-17.49M | $29.60M | $29.26M | $47.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-11.19M | $35.99M | $35.66M | (m) | $47.19M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-10.14M | $37.16M | $36.84M | (m) | $47.30M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-11.02M | $36.36M | $36.05M | (m) | $47.38M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-11.21M | $36.27M | $35.97M | $47.47M | $47.47M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-8.77M | $38.76M | $38.89M | (m) | $47.53M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-8.36M | $39.46M | $39.20M | (m) | $47.82M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-7.02M | $41.02M | $40.79M | (m) | $48.05M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-5.64M | $42.81M | $42.60M | $48.45M | $48.45M | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-1.79M | $46.82M | $46.65M | (m) | $48.61M | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-735.62K | $47.95M | $47.81M | (m) | $48.69M | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-1.96M | $47.02M | $46.88M | (m) | $48.98M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-2.13M | $46.99M | $46.87M | $49.12M | $49.12M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-1.25M | $47.93M | $47.84M | (m) | $49.18M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-765.50K | $48.48M | $48.41M | (m) | $49.25M | (m) | (m) | (m) | (m) |
| 2020-03-31 | $152.78K | $49.89M | $49.84M | (m) | $49.74M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $1.21M | $51.12M | $51.09M | $49.91M | $49.91M | (m) | (m) | 12 month · $1.00M | (m) |
| 2019-09-30 | $2.17M | $51.73M | $51.71M | (m) | $49.56M | (m) | (m) | 9 month · $1.00M | (m) |
| 2019-06-30 | $4.12M | $54.06M | $53.69M | (m) | $49.94M | (m) | (m) | (m) | (m) |
| 2019-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $1.00M |
| 2019-03-31 | $4.67M | $55.43M | $55.19M | (m) | $50.76M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.75M | $55.84M | $55.57M | $51.10M | $51.10M | (m) | (m) | (m) | (m) |
| 2018-09-30 | $6.97M | $58.20M | $57.94M | (m) | $51.24M | (m) | (m) | 9 month · $0.00 | (m) |
| 2018-06-30 | $8.61M | $59.91M | $59.67M | (m) | $51.30M | (m) | (m) | (m) | (m) |
| 2018-03-31 | $9.33M | $61.09M | $60.87M | (m) | $51.76M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $11.71M | $64.12M | $63.92M | $52.41M | $52.41M | (m) | (m) | (m) | (m) |
| 2017-09-30 | $12.51M | $65.10M | $64.92M | (m) | $52.59M | (m) | (m) | (m) | (m) |
| 2017-06-30 | $13.25M | $66.66M | $66.49M | (m) | $53.40M | (m) | (m) | (m) | (m) |
| 2017-03-31 | $18.41M | $72.36M | $72.21M | (m) | $53.95M | (m) | (m) | (m) | (m) |
| 2016-12-31 | $18.60M | $73.25M | $73.12M | $54.64M | $54.64M | (m) | (m) | (m) | 12 month · $1.00M |
| 2016-09-30 | $19.35M | $74.53M | $74.42M | (m) | $55.18M | (m) | (m) | (m) | (m) |
| 2016-06-30 | $19.25M | $74.47M | $74.37M | (m) | $55.22M | (m) | (m) | (m) | (m) |
| 2016-03-31 | $19.30M | $75.40M | $75.32M | (m) | $56.11M | (m) | (m) | (m) | (m) |
| 2015-12-31 | $19.55M | $76.89M | $76.82M | $57.34M | $57.34M | (m) | (m) | (m) | 12 month · $1.00M |
| 2015-09-30 | $19.40M | $77.59M | $77.54M | (m) | $58.19M | (m) | (m) | (m) | (m) |
| 2015-06-30 | $19.27M | $78.74M | $78.70M | (m) | $59.47M | (m) | (m) | (m) | (m) |
| 2015-03-31 | $18.86M | $79.37M | $79.34M | (m) | $60.51M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $18.82M | $80.76M | $80.75M | $61.94M | $61.94M | (m) | (m) | (m) | 12 month · $1.00M |
| 2014-09-30 | $18.15M | $81.10M | $80.89M | (m) | $62.95M | (m) | (m) | (m) | 9 month · $1.00M |
| 2014-06-30 | $17.40M | $80.93M | $80.73M | (m) | $63.53M | (m) | (m) | (m) | 6 month · $1.00M |
| 2014-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $1.00M |
| 2014-03-31 | $16.68M | $79.15M | $78.96M | (m) | $62.47M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $16.39M | $79.47M | $79.29M | $63.07M | $63.07M | (m) | (m) | (m) | (m) |
| 2013-09-30 | $17.89M | $81.10M | $80.93M | $80.93M | $63.20M | (m) | (m) | (m) | (m) |
| 2013-06-30 | $18.71M | $83.03M | $82.87M | $82.87M | $64.31M | (m) | (m) | (m) | (m) |
| 2013-03-31 | $19.35M | $85.17M | $85.03M | $85.03M | $65.82M | (m) | (m) | (m) | (m) |
| 2012-12-31 | $18.50M | $85.70M | $85.57M | $67.20M | $67.20M | (m) | (m) | (m) | (m) |
| 2012-09-30 | $16.69M | $83.45M | $83.33M | $83.33M | $66.76M | 9 month · $455.67K | (m) | (m) | (m) |
| 2012-06-30 | $14.82M | $83.32M | $83.21M | $83.21M | $68.50M | 6 month · $315.34K | (m) | (m) | (m) |
| 2012-03-31 | $13.08M | $81.95M | $81.85M | $81.85M | $68.87M | (m) | (m) | (m) | (m) |
| 2011-12-31 | $12.66M | $82.93M | $82.84M | $70.27M | $70.27M | (m) | (m) | (m) | (m) |
| 2011-09-30 | $11.74M | $83.55M | $83.46M | $83.46M | $71.80M | (m) | (m) | (m) | (m) |
| 2011-06-30 | $9.90M | $81.51M | $81.43M | $81.43M | $71.61M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $7.00M | $77.78M | $77.72M | $77.72M | $70.78M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $72.22M | $72.22M | (m) | (m) | 12 month · $97.58K | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | $17.55M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |